SiteOne Therapeutics, headquartered in Bozeman, Montana with a research team in San Francisco, California, is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (NaV1.7) inhibitors based on naturally occurring small molecules. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.
Bozeman, US
SiteOne Therapeutics was founded in 2010 and is headquartered in Bozeman, US
Report incorrect company information

SiteOne Therapeutics Office Locations

SiteOne Therapeutics has an office in Bozeman
Bozeman, US (HQ)
3 203 Enterprise Blvd
Show all (1)
Report incorrect company information

SiteOne Therapeutics Financials and Metrics

Summary Metrics

Founding Date


SiteOne Therapeutics total Funding

$17.8 m

SiteOne Therapeutics latest funding size

$15 m

Time since last funding

2 years ago

SiteOne Therapeutics investors

SiteOne Therapeutics's latest funding round in January 2017 was reported to be $15 m. In total, SiteOne Therapeutics has raised $17.8 m
Show all financial metrics
Report incorrect company information

SiteOne Therapeutics Company Life and Culture

Report incorrect company information